Please login to the form below

Not currently logged in
Email:
Password:

Novartis reveals USD 400m of further cuts

Novartis reveals plans to make additional savings of USD 400m at its pharmaceutical business in addition to the previously announced USD 1bn of cuts

Swiss-based pharmaceutical company Novartis has revealed plans to make additional savings of USD 400m at its pharmaceutical business in addition to the previously announced USD 1bn of cuts, according to local media reports.

The SonntagsZeitung newspaper said that Novartis' head of pharmaceuticals, Thomas Ebeling, had confirmed the new plans in discussions with analysts at the group's Pharma Brand and Business Review on 12 September.

Novartis instituted the cuts to make savings in marketing and sales, where costs rose 11 per cent in 2006.

The newspaper also reported that Novartis was going to make big cuts in its US salesforce after recent product setbacks, after the company expanded it by between 6,000-7,000 in 2006.

17th September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...